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Abstract 
Background. Patients’ understanding of treatment risks and benefits is a prerequisite for shared 
decision-making. Yet, patients with Multiple Sclerosis (MS) do not accurately understand treatment 
information provided in regular clinical consultations.   
Objective. To identify the best methods of communicating clinical trial data to improve MS patients’ 
understanding of treatments. To also examine the relationship between patients’ understanding with 
decisional conflict, individual traits and MS symptoms.  
Design. A repeated-measures study was employed. Patients were presented with hypothetical 
treatment risks and benefits from faux clinical trials. Treatments were communicated using absolute 
terms, relative terms and numbers needed to treat/harm. The presence of baseline information with 
each method was also manipulated. Patients’ understanding and conflict in treatment decisions was 
assessed. Individual traits and MS symptoms were also recorded. 
Participants. A sample of relapsing-remitting MS patients from NHS sites in the UK. 
Results. Understanding was better when treatments were communicated in absolute terms (M=3.99, 
SD=.93) compared to relative terms (M=2.93, SD=.91, p<.001) and numbers needed to treat/harm 
(M=2.89, SD=.88, p<.001). Adding baseline information to all methods significantly improved 
understanding (M=5.04, SD=.96) compared to no baseline information (M=1.50, SD=.74, p<.001). 
Understanding was not related to conflict in treatment decisions (r=-.131, p=.391). Numeracy, IQ and 
cognitive impairments were significantly related to patients’ understanding of treatments.  
Conclusion. Treatment risks and benefits should ideally be communicated using absolute terms, 
alongside baseline information. MS patients with low numeracy, low IQ and reduced cognitive skills 
should be supported during treatment education.
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Introduction 
Shared decision-making is advocated in patient-centred healthcare as an ideal approach for making 
treatment decisions [1,2]. A prerequisite to shared treatment decisions is patients’ understanding of 
available treatments. Accurate treatment knowledge can ensure patients engage with the decision-
making process [3], choose a treatment that aligns with their values [2], and adhere to their chosen 
treatment [4]. Good treatment knowledge can also reduce decisional conflict, which encompasses the 
feeling of uncertainty in a treatment choice [5-7]. However, not all patient groups show accurate 
understanding of treatment risks and benefits. 
Multiple Sclerosis (MS) is a chronic inflammatory condition of the central nervous system, often leading 
to advanced neurological disability [8,9]. Patients with MS are faced with important decisions about 
disease-modifying drugs (DMDs), which can help delay disease progression. However, MS patients find it 
particularly challenging to understand DMD information during routine healthcare [10]. One reason may 
be the complex risk-benefit profiles associated with DMDs. For instance, while some DMDs are 
moderately effective with low risks, other DMDs offer higher efficacy in exchange for higher risks to 
patients [11]. It is also possible that individual traits and some MS symptoms can confound patients’ 
understanding of treatments. Intelligence, numeracy and health literacy can typically influence 
comprehension of treatments [12-15]. Cognitive deficits, prevalent in 40-70% of MS patients [15], can 
further affect understanding [16]. Other commonly experienced MS symptoms, such as depression, 
anxiety and fatigue [17] may also influence understanding, but have not been previously assessed. It is 
essential then that understanding of DMDs be improved for MS patients. 
Understanding of treatment information derived from clinical trials can be affected by the methods in 
which this is communicated. Differences between risks and benefits experienced by a patient group 
taking a new treatment and another patient group taking a placebo during a clinical trial, can be 
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communicated in absolute terms (conveying true differences), relative terms (conveying proportional 
differences) and numbers needed to treat/harm (conveying the average number of patients to take the 
treatment for one person to experience an outcome). Absolute terms have been shown to improve 
understanding compared to other methods in non-clinical [18,19] and clinical populations [20,21]. With 
the addition of baseline information (i.e. the original number of patients in both groups that experience 
the risk or benefit), understanding improved regardless of the method [18,19,21]. The only study 
conducted with MS patients found better understanding when baseline information was added to 
absolute terms, but did not examine other methods [22]. There is still a need to systematically 
investigate all methods with MS patients. 
This study is the last of three experiments investigating optimal methods of communicating treatment 
information to MS patients, to culminate in an educational intervention. Previous two experiments 
examined numerical and graphical methods, type of frequencies and ways of framing treatment risks 
and benefits. The main objective of the current study was to identify the best method of communicating 
clinical trial data. Specific hypotheses were as follows: (i) absolute terms would improve understanding, 
(ii) baseline information would improve understanding, (iii) patients’ decisional conflict would reduce 





Patients were recruited from two UK National Health Clinics (NHS). Patients diagnosed with relapsing-
remitting MS, taking a DMD, able to provide informed consent and meet study sensorimotor task 
demands were included. There was no selection on the basis of cognitive impairment. Patients were 
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excluded if their condition or medication had changed in the last four weeks, or if they had a significant 
medical and/or psychiatric condition besides MS. Patients had visual acuity of at least 20/70 [23]. The 
study received ethical approval from the NHS Research Ethics Committee. 
Materials  
Patients were presented with a hypothetical disease with progressive characteristics similar to MS. Two 
hypothetical treatments were provided for this disease. Treatment risk-benefit profiles were based on 
DMD clinical trials [e.g. 24,25], to mimic real clinical decisions. Risks and benefits were presented for 1, 2 
and 5 years of taking the treatment. Each treatment had one minor risk (e.g. flu-like symptoms), one 
adverse risk (e.g. kidney failure) and one benefit (delays in progression of disease symptom).  
Design 
A repeated-measures design was employed. Treatment risks and benefits were communicated using six 
different methods: absolute terms, relative terms and numbers needed to treat/harm, each with or 
without baseline information (see figure 1). Three methods were randomly assigned to each treatment 
at the beginning of the study. Treatment order was counterbalanced between patients using a latin-
square design [26]. The study was conducted with the chief investigator (GR). The session took between 
1.5-2 hours and included multiple breaks for patients as required.  
Measures  
Primary outcome measure. 
Understanding 
Six questions assessed understanding immediately after a treatment risk or benefit. Questions were 
author-developed but adapted from previous studies [27-29]. Patients first reported the number of 
people who experienced the risk/benefit of the treatment over the three time periods. Answers were 
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deemed correct if within 10% of the precise value [27,28]. Patients then stated the differences in 
risks/benefits between the treatment and placebo group over the three time periods. This was a 
multiple-choice question, with one correct answer out of four possible options.  
Secondary outcome measures. 
Decisional conflict 
Patients were asked to make a treatment decision: choose a treatment, choose no treatment or state 
that they were unsure. Conflict in decisions was recorded using the patient-reported Decisional Conflict 
Scale (DCS), validated for use in healthcare decisions [5]. The scale consists of 16 items divided into 5 
subscales: uncertainty, feeling uninformed, values, support and effective decision.  
Individual traits and MS symptoms 
Patient demographics, disease variables and disability status [31] were recorded. A short 8-item word 
recognition task assessed health literacy: the Rapid Estimate of Adult Literacy in Medicine - Revised [32] 
(REALM-R). Numeracy was assessed by the arithmetic subtask from the Verbal and Spatial reasoning 
scale [33] (VESPAR). Hospital Anxiety and Depression Scale [34] (HADS) assessed affective MS symptoms, 
and has been validated for use with MS patients [35]. Fatigue was assessed via the patient-reported 
Fatigue Severity Scale [36] (FSS), originally developed for the MS population [36]. The Wechsler Test of 
Adult Reading scale [37] (WTAR) measured premorbid intelligence, which is not altered by cognitive 
deficits [38]. The Brief International Cognitive Assessment for Multiple Sclerosis [39] (BICAMS) identified 
cognitive impairments. 
Analysis 
Sample size estimates were based on a questionnaire which found large effects on MS patients’ 
understanding [40]. Since only a few questionnaire items specifically assessed treatment knowledge, a 
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medium effect size (Cohens d of 0.5, [41]) was assumed. It was estimated that for an alpha of 0.05 and 
power of 0.80, a minimum of 45 patients were required. 
All statistical analyses were conducted in SPSS 21. A two-way ANOVA assessed the impact of methods 
on patients’ understanding of treatments. Bonferroni corrections were applied for pairwise 
comparisons. Pearson’s product-moment correlations examined the relationship between 
understanding with standardised DCS scores, individual traits and MS symptoms.  
 
Results 
Of 82 eligible patients approached for the study, 45 patients agreed to participate (54.9% response 
rate). Patient demographics are reported in Table 1.  
The effect of (i) methods and (ii) baseline information on understanding 
Average understanding scores for each method were as follows: absolute terms (baseline, M=5.40, 
SD=1.03; no baseline, M=2.58, SD=1.22), relative terms (baseline, M=4.98, SD=1.39; no baseline, 
M=0.89, SD=0.96) and numbers needed to treat/harm (baseline, M=4.76, SD=1.32; no baseline, M=1.02, 
SD=1.12). 
When collapsing across baseline and no baseline conditions, there was a significant main effect of 
methods on patients’ understanding, F(2,88)=36.03 p<.001, partial η2=.45. Understanding was greater 
for absolute terms (M=3.99, SD=.93), compared to relative terms (M=2.93, SD=.91, p<.001) and numbers 
needed to treat/harm (M=2.89, SD=.88). There was no significant difference between relative terms and 
numbers needed to treat/harm (p=.745).  
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When collapsing across methods, there was a significant main effect of baseline information on patients’ 
understanding, F(1,44)=577.74, p<.001, partial η2=.93, with greater understanding for baseline 
information (M=5.04, SD=.96) than no baseline information (M=1.50, SD=.74).  
There was a significant interaction between methods and baseline information F(1,44)=9.62, p<.001, 
partial η2=.18. Adding baseline information to all methods improved understanding. 
(iii) Relationship between understanding and decisional conflict 
There was no significant correlation between understanding and patients’ decisional conflict (r=-.131, 
p=.391) or any DCS subscales.  
(iv) Relationship between understanding with individual traits and MS symptoms 
Patients mostly showed symptoms of fatigue and cognitive impairments (see supplementary table). 
Understanding was significantly correlated with numeracy (r=.517, p<.001), premorbid IQ (r=.434, 
p<.01), information processing speed (r=.439, p<.01) and verbal memory (r=.409, p<.01). 
 
Discussion 
Patients’ ability to understand treatment information is a prerequisite for effective shared decision-
making [1,2]. Yet, MS patients do not accurately understand treatment risks and benefits in regular 
clinical practise [10]. The current study sought to determine the most effective method of 
communicating treatment information derived from clinical trials to MS patients. As predicted, absolute 
terms led to better understanding of treatments compared to other methods. Baseline information 
substantially improved understanding for all methods. However, understanding was not related to 
patients’ conflict in treatment decisions. 
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Understanding of treatments was low when communicated in relative terms and numbers needed to 
treat/harm. Relative terms usually result in larger figures than absolute terms and may be 
misinterpreted for the latter. This is supported by patients’ likelihood of selecting a treatment when 
benefits are communicated in relative terms instead of absolute terms [42]. Low understanding for 
numbers needed to treat/harm may be explained by its similarity to the 1-in-X format (e.g. 1 in 20, 1 in 
75), shown to reduce understanding of treatments [43,44]. These methods should be avoided when 
communicating treatments to MS patients. 
The current study showed no relationship between patients’ understanding of treatments and 
decisional conflict or the DCS informed subscale, inconsistent with previous studies [5-7]. The absence of 
this relationship may be a result of differences in perceived knowledge measured by the DCS and 
objective understanding assessed in the current study [5,7]. Although the DCS has been validated for 
real and hypothetical decisions [5], it is also possible that patients’ decisional conflict may differ for 
decisions which can have real consequences. Nevertheless, MS patients expressing low conflict in 
decisions should not be assumed to have good treatment knowledge.  
As predicted, understanding of treatments showed a relationship with patients’ numeracy and pre-
morbid IQ. Health literacy did not show a relationship, possibly due to the measure being too short. 
With regards to MS symptoms, only cognitive impairments showed a relationship with patients’ 
understanding. A simple assessment of cognition within clinical practice, such as BICAMS [56], could 
help identify patients requiring support during treatment decision-making. However, this study was not 
powered to detect relationships between understanding and MS symptoms. Thus, support for patients 
with affective symptoms and fatigue should not be ruled out.  
Findings of the current study should be interpreted in light of its limitations. First, hypothetical 
treatments were provided to avoid risking patients to new or conflicting information about current 
medication. However, outcomes may differ for real treatments in which patients feel emotionally 
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invested and should be evaluated in future work. Second, treatment information was provided in a 
setting not reflective of a regular consultation, to allow for a systematic assessment of different 
methods. With the best methods established and incorporated into an educational intervention, future 
work can implement this in real consultations. Finally, the effect of fatigue and cognitive burden on 
study outcomes cannot be excluded. Possible effects were minimised by providing breaks and 
counterbalancing treatments between patients. Fatigue could have influenced scores on BICAMS [44], 
which was always conducted last in the study. Since BICAMS as a stringent measure identified only mild 
cognitive impairments in the current patient group, any cognitive burden may have had only a small 
effect on study outcomes. 
Conclusion 
The current study is the first to evaluate the best methods of communicating treatment risks and 
benefits derived from clinical trials to MS patients. Good understanding was evident for treatments 
expressed in absolute terms and with baseline information. MS patients with low numeracy, low IQ and 
cognitive deficits should be supported during treatment education. 
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Table 1 Patient demographics and disease status (n=45) 
 Mean (SD) n (%) 
Age, years 46.76 (10.50)  
Gender   
Female  36 (80.0) 
Male  9 (20.0) 
Level of education   
High school  15 (33.3) 
College   11 (24.4) 
Bachelor’s degree  8 (17.8) 
Postgraduate  11 (24.4) 
Employment status   
Full-time (>16 hours)  13 (28.9) 
Part-time (<16 hours)  10 (22.2) 
Self-employed  7 (15.6) 
Unemployed  11 (24.4) 
Medical leave  3 (6.7) 
Retired  1 (2.2) 
Time since MS diagnosis, years 10.68 (8.51)  
HAI disability scale 1.64 (1.77)  
Current DMD   
Interferon betas  15 (33.3) 
Glatiramer Acetate  4 (8.9) 
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 Mean (SD) n (%) 
Teriflunomide  0 (0) 
Fingolimod  8 (17.8) 
Alemtuzumab  4 (8.9) 
Dimethyl Fumarate  5 (11.1) 
Natalizumab  8 (17.8) 
Mitoxantrone  1 (2.2) 
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Figure 1 Example showing the following methods to communicate clinical trial data: baseline 
information, absolute terms, relative terms and numbers needed to treat/harm; Example of treatment 
risk only  
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Supplementary table Patients impaired on assessments (n=45) and correlations between individual 
traits and MS symptoms with total understanding score  
 Max 
score 




Numerical reasoning 25 16.36 (3.80) 3 (6.7) .517*** 
Health literacy 8 7.42 (1.32) 6 (13.3) .273 
Depression 21 4.11 (3.69) 1 (2.2) -.257 
Anxiety 21 6.27 (3.98) 5 (11.1) -.348* 
Fatigue 63 44.00 (13.47)  22 (48.9) -.123 
Premorbid IQ 50 36.69 (8.46) 3 (6.7) .434** 
Info processing speed 110 56.62 (12.62) 14 (31.1) .439** 
Verbal memory 80 49.07 (12.43) 15 (33.3) .409** 
Visual memory 36 21.16 (6.46) 23 (51.1) .287 
* = indicates significance at the p<.05 level; ** at p<.01 level; *** at p<.001 level;  
correlations in bold accepted as significant 
 
 
 
 
 
